The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VII.a

Lymphadenopathy (intrathoracic)

Publications

Abbondazo SL, Irey NS, Frizzera G

Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns.

The American journal of surgical pathology. 1995;19(6):675-86

Abratt RP, Sealy R, Uys CJ, Lawson R

Lymphadenopathy associated with diphenylhydantoin therapy.

Clinical oncology. 1982;8(4):351-6

Yermakov VM, Hitti IF, Sutton AL

Necrotizing vasculitis associated with diphenylhydantoin: two fatal cases.

Human pathology. 1983;14(2):182-4

Rubinstein I, Baum GL, Hiss Y, Goldhammer Y

Does prolonged use of diphenylhydantoin predispose to pulmonary sarcoidosis?

European neurology. 1986;25(4):281-4

Vesin P, Periac P, Kalifat R, Intrator L, Tuilliez M, Cattan D

[Lymphadenopathies and protein anomalies following phenylhydantoine therapy].

La Nouvelle presse medicale. 1976;5(17):1125-7